Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Xolair 150mg Powder and Solvent for Solution for Injection - HSA Drug Approval Details

Approvals/HSA/Xolair 150mg Powder and Solvent for Solution for Injection

Approved

THERAPEUTIC

Xolair 150mg Powder and Solvent for Solution for Injection

Takeda Austria GmbH (AUSTRIA)Novartis Pharma Stein AG (SWITZERLAND)DELPHARM DIJON - QUETIGNY (FRANCE)🇸🇬 Health Sciences Authority

Approval Date: Jul 7, 2006
Approval ID: bc401b03110fd46e
Company: Takeda Austria GmbH (AUSTRIA)Novartis Pharma Stein AG (SWITZERLAND)DELPHARM DIJON - QUETIGNY (FRANCE)
Type: Therapeutic

Approval Details

Approval Id: bc401b03110fd46e
Drug Name: Xolair 150mg Powder and Solvent for Solution for Injection
Product Name: Xolair 150mg Powder and Solvent for Solution for Injection
Approval Number: SIN13212P
Approval Date: 2006-07-07
Registrant: NOVARTIS (SINGAPORE) PTE LTD
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route Of Administration: SUBCUTANEOUS
Atc Code: R03DX05
Atc Item Name: omalizumab
Pharma Manufacturer Name: NOVARTIS (SINGAPORE) PTE LTD

Active Ingredients

Omalizumab

150mg

Omalizumab

150mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jul 7, 2006

Approval ID

bc401b03110fd46e

Type

Therapeutic

Back to HSA Approvals